Search research articles
Contact Us
Filters
Showing results (31-40 of 51) with videos related to
Page
of 6
Sort By:
Cancer Research
|
July 12, 2020
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction
Hanumantha Rao Madala, Iiro Taneli Helenius, Wen Zhou, et al.
Cancer Discovery
|
February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia
Alan H Shih, Cem Meydan, Kaitlyn Shank, et al.
Nature Immunology
|
November 8, 2005
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin
Andrew M Intlekofer, Naofumi Takemoto, E John Wherry, et al.
Genes & Development
|
September 26, 2013
Induction of sarcomas by mutant IDH2
Chao Lu, Sriram Venneti, Altuna Akalin, et al.
Science Advances
|
June 22, 2022
Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma
Ian Ganly, Eric Minwei Liu, Fengshen Kuo, et al.
Haematologica
|
September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Cancer Discovery
|
April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Jacob L Glass, Duane Hassane, Bas J Wouters, et al.
Leukemia & Lymphoma
|
July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
Efrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Cellular & Molecular Immunology
|
January 17, 2024
CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity
G Aaron Holling, Colin A Chavel, Anand P Sharda, et al.
The Journal of Clinical Investigation
|
January 23, 2018
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Anna Sophia McKenney, Allison N Lau, Amritha Varshini Hanasoge Somasundara, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 51) with videos related to
Sort By:
Page
of 6
Cancer Research
|
July 12, 2020
Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction
Hanumantha Rao Madala, Iiro Taneli Helenius, Wen Zhou, et al.
Cancer Discovery
|
February 15, 2017
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i>- and <i>TET2</i>-Mutant Acute Myeloid Leukemia
Alan H Shih, Cem Meydan, Kaitlyn Shank, et al.
Nature Immunology
|
November 8, 2005
Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin
Andrew M Intlekofer, Naofumi Takemoto, E John Wherry, et al.
Genes & Development
|
September 26, 2013
Induction of sarcomas by mutant IDH2
Chao Lu, Sriram Venneti, Altuna Akalin, et al.
Science Advances
|
June 22, 2022
Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma
Ian Ganly, Eric Minwei Liu, Fengshen Kuo, et al.
Haematologica
|
September 5, 2024
Rituximab and lenalidomide for the treatment of relapsed or refractory indolent non-Hodgkin lymphoma: real-life experience
Giulio Cassanello, Esther Drill, Alfredo Rivas-Delgado, et al.
Cancer Discovery
|
April 15, 2017
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers
Jacob L Glass, Duane Hassane, Bas J Wouters, et al.
Leukemia & Lymphoma
|
July 2, 2025
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis
Efrat Luttwak, Edith Tama Robin, Esther Drill, et al.
Cellular & Molecular Immunology
|
January 17, 2024
CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity
G Aaron Holling, Colin A Chavel, Anand P Sharda, et al.
The Journal of Clinical Investigation
|
January 23, 2018
JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Anna Sophia McKenney, Allison N Lau, Amritha Varshini Hanasoge Somasundara, et al.
Page
of 6